Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19806480 | 0.86 | TGFBR1 (0.60) | TGFBR1GRM2DYRK1ACYP1A2METAP2 | |
| SCHEMBL19806337 | 0.83 | TGFBR1 (0.51) | TGFBR1PDE4APDE3ACYP3A4HPGD | |
| SCHEMBL13874033 | 0.82 | TGFBR1 (0.48) | TGFBR1PDE4APDE3ACYP3A4HPGD | |
| SCHEMBL15638144 | 0.82 | TGFBR1 (0.59) | TGFBR1GRM2PDE4APDE3ACYP3A4 | |
| SCHEMBL19806559 | 0.81 | DYRK1A (0.46) | TGFBR1GRM2PDE4APDE3ACYP3A4 | |
| SCHEMBL18041976 | 0.78 | TGFBR1 (0.51) | TGFBR1GRM2PDE4APDE3ACYP3A4 | |
| SCHEMBL29677080 | 0.78 | TGFBR1 (0.51) | TGFBR1GRM2PDE4APDE3ACYP3A4 | |
| SCHEMBL19806364 | 0.78 | TGFBR1 (0.45) | TGFBR1GRM2PDE4APDE3ACYP3A4 | |
| SCHEMBL8948378 | 0.78 | TGFBR1 (0.50) | TGFBR1PDE4APDE3ACYP3A4HPGD | |
| SCHEMBL19806383 | 0.77 | TGFBR1 (0.45) | TGFBR1GRM2TGFBR2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018017633-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885GRM2 1261/4885PDE4A 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.